Home Neoplasma 2020 Neoplasma Vol.67, No.3, p.484–491, 2020

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.67, No.3, p.484–491, 2020

Title: RGMB-AS1/miR-22-3p/NFIB axis contributes to the progression of gastric cancer
Author: W. ZHANG, F. ZHAN, D. LI, T. WANG, H. HUANG

Abstract: Gastric cancer (GC), one of the most common cancers worldwide, presents a considerable threat to human health. Although multiple investigations have been made to figure out therapies for this disease, the prognosis of patients suffered from GC remains poor. It has been reported that lncRNAs exerted their significant effects on numerous cancers. Evidence confirmed that lncRNA RGMB-AS1 played an oncogenic role in the progression of cancers. However, the biological function and molecular mechanism of RGMB-AS1 in GC haven’t been explored. In this study, our results demonstrated that RGMB-AS1 was upregulated in GC cells and knockdown of RGMB-AS1 suppressed cell proliferation, migration, invasion, EMT process and promoted cell apoptosis. Molecular mechanism experiments indicated that RGMB-AS1 could bind with miR-22-3p and NFIB was a downstream target gene of miR-22-3p. Additionally, RGMB-AS1 suppression upregulated the expression of miR-22-3p and miR-22-3p inhibitor could reverse the inhibitive role of sh-RGMB-AS1-1 in NFIB expression. Rescues assays showed that NFIB overexpression partially recovered the inhibitory function on cell proliferation, migration, invasion, EMT process and the promotive function on cell apoptosis caused by RGMB-AS1 depletion. Taken together, RGMB-AS1 contributes to the progression of GC by regulating miR-22-3p/NFIB axis, indicating a new therapeutic target for GC treatment.

Keywords: RGMB-AS1, miR-22-3p, NFIB, gastric cancer
Published online: 15-May-2020
Year: 2020, Volume: 67, Issue: 3 Page From: 484, Page To: 491
doi:10.4149/neo_2020_190418N350


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.